UM  > Institute of Chinese Medical Sciences
Affiliated with RCfalse
Status已發表Published
Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines
Lu,Peng De1; Zhao,Yong Hua2
2020-02-10
Source PublicationChinese Medicine
Volume15Pages:15
Abstract

Nuclear factor-kappa B (NF-κB) is a kind of multi-functional nuclear transcription factor involved in regulating gene transcription to influence pathological evolution of inflammatory and immune diseases. Numerous literature evidence that NF-κB pathway plays an essential role in pathogenic development of ulcerative colitis (UC). UC is a chronic non-specific inflammatory bowel disease, and until now, therapeutic agents for UC including aminosalicylates, corticosteroids and immune inhibitors still cannot exert satisfied effects on patients. In recent years, Chinese medicines suggest the advantages of alleviating symptoms and signs, decreasing side-effects and recurrence, whose one of mechanisms is related to regulation of NF-κB pathway. In this review, we categorize Chinese medicines according to their traditional therapeutic functions, and summarize the characteristics of Chinese medicines targeting NF-κB pathway in UC treatment. It indicates that 85 kinds of Chinese medicines' compounds and formulae can directly act on NF-κBp65; while 58 Chinese medicines' ingredients and formulae indirectly suppress NF-κBp65 by regulation of its upstream or other related pathways. Moreover, by the analysis of Chinese medicines' category based on their traditional functions, we conclude the category of dampness-drying and detoxificating medicine targeting NF-κB pathway accounts for primary status for amelioration of UC. Simultaneously, this review also contributes to the choices of Chinese medicine category and provides curative potential of Chinese medicines for clinical UC treatment.

KeywordCharacteristics Chinese Medicines Nf-κb Ulcerative Colitis
DOI10.1186/s13020-020-0296-z
URLView the original
Indexed BySCIE
Language英語English
WOS Research AreaIntegrative & Complementary Medicine ; Pharmacology & Pharmacy
WOS SubjectIntegrative & Complementary Medicine ; Pharmacology & Pharmacy
WOS IDWOS:000520428700001
Scopus ID2-s2.0-85079225425
Fulltext Access
Citation statistics
Cited Times [WOS]:45   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorZhao,Yong Hua
Affiliation1.School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine,Guangzhou,China
2.State Key Laboratory of Quality Research in Chinese Medicine,Institute of Chinese Medical Sciences,University of Macau,Taipa,999078,Macao
Corresponding Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Lu,Peng De,Zhao,Yong Hua. Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines[J]. Chinese Medicine,2020,15:15.
APA Lu,Peng De,&Zhao,Yong Hua.(2020).Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines.Chinese Medicine,15,15.
MLA Lu,Peng De,et al."Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines".Chinese Medicine 15(2020):15.
Files in This Item: Download All
File Name/Size Publications Version Access License
Targeting NF-κB path(1363KB)期刊论文作者接受稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Lu,Peng De]'s Articles
[Zhao,Yong Hua]'s Articles
Baidu academic
Similar articles in Baidu academic
[Lu,Peng De]'s Articles
[Zhao,Yong Hua]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Lu,Peng De]'s Articles
[Zhao,Yong Hua]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Targeting NF-κB pathway for treating ulcerative colitis.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.